Bill Text: IL HB2846 | 2019-2020 | 101st General Assembly | Chaptered


Bill Title: Amends the Illinois Insurance Code. In provisions concerning treatment for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, provides that treatment administered or prescribed after July 18, 2017 shall be covered. Provides that for billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall be coded as autoimmune encephalitis until a code is assigned. Provides that coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may not be denied due to a diagnosis of autoimmune encephalopathy or autoimmune encephalitis. Effective immediately.

Spectrum: Moderate Partisan Bill (Democrat 23-6)

Status: (Passed) 2019-08-23 - Public Act . . . . . . . . . 101-0488 [HB2846 Detail]

Download: Illinois-2019-HB2846-Chaptered.html



Public Act 101-0488
HB2846 EnrolledLRB101 09717 RAB 54817 b
AN ACT concerning regulation.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Insurance Code is amended by
changing Section 356z.25 as follows:
(215 ILCS 5/356z.25)
Sec. 356z.25. Coverage for treatment of pediatric
autoimmune neuropsychiatric disorders associated with
streptococcal infections and pediatric acute onset
neuropsychiatric syndrome. A group or individual policy of
accident and health insurance or managed care plan that is
amended, delivered, issued, or renewed after July 18, 2017 (the
effective date of Public Act 100-24) shall provide coverage for
treatment of pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections and pediatric
acute-onset neuropsychiatric syndrome, including, but not
limited to, the use of intravenous immunoglobulin therapy.
For billing and diagnosis purposes, pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infections and pediatric acute onset neuropsychiatric syndrome
shall be coded as autoimmune encephalitis until the American
Medical Association and the Centers for Medicare and Medicaid
Services create and assign a specific code for pediatric
autoimmune neuropsychiatric disorders associated with
streptococcal infections and pediatric acute onset
neuropsychiatric syndrome. Thereafter, pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infections and pediatric acute onset neuropsychiatric syndrome
may be coded as autoimmune encephalitis, pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infections, or pediatric acute onset neuropsychiatric
syndrome.
If, at any time, the Secretary of the United States
Department of Health and Human Services, or its successor
agency, promulgates rules or regulations to be published in the
Federal Register or publishes a comment in the Federal Register
or issues an opinion, guidance, or other action that would
require the State, pursuant to any provision of the Patient
Protection and Affordable Care Act (Public Law 111-148),
including, but not limited to, 42 U.S.C. 18031(d)(3)(B) or any
successor provision, to defray the cost of any coverage for
pediatric autoimmune neuropsychiatric disorders associated
with streptococcal infections and pediatric acute onset
neuropsychiatric syndrome outlined in this Section, then the
requirement that an insurer cover pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infections and pediatric acute onset neuropsychiatric syndrome
is inoperative other than any such coverage authorized under
Section 1902 of the Social Security Act, 42 U.S.C. 1396a, and
the State shall not assume any obligation for the cost of
coverage for pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections and pediatric acute
onset neuropsychiatric syndrome.
(Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18.)
Section 99. Effective date. This Act takes effect upon
becoming law.
feedback